Physicians in the North Central states are doing the best of all the nation’s physicians when it comes to compensation, according to Medscape’s “Physician Compensation Report 2011.”

That would be the Dakotas, Iowa, Missouri, Kansas and Nebraska. Why? “While over the years the disparity of compensation between regions has narrowed, certain specialties still earn more in the middle of the country,” says Tommy Bohannon, vice president for hospital-based recruiting at Merritt Hawkins. “In particular, the more procedurally-oriented fields [gastroenterology, orthopedic surgery, general surgery, and urology] are doing better than in other parts of the country while primary care specialties are lagging. When you factor in less competition, an increasing amount of hospital subsidy, and lower overall costs to run a practice, the heartland is generally the place to look” if you are a physician seeking to earn more money.

Physician compensation by geographic area

Meanwhile, there may be a shortage of primary care physicians but there’s apparently no shortage of primary care angst about payment. When asked if they feel they are being fairly compensated, 52 percent of PCPs say no. An almost equal percentage of physicians in 22 specialties, on the other hand, say they are fairly compensated. “While the shortage of PCPs is leading to better salaries due to difficulty recruiting, it’s not enough to offset the gap in pay,” says Bohannon.

Do physicians feel fairly compensated?

Medscape says that 41 percent of PCPs spend 30–40 hours a week seeing patients, 37 percent spend 41–50 hours a week, and 23 percent spend 51–65 hours. Of course, hours are made up of minutes and the study shows that about 30 percent of PCPs spend 13–16 minutes with each patient. “We’re reaching a point where many of these practices simply can’t handle more patient volume without either expanding provider supply or further extending the hours of their current providers,” says Bohannon. “Recruiting is becoming more and more challenging in primary care.”

Minutes spent with each patient

Note: 15,794 physicians in 22 specialties were surveyed by Medscape between Feb. 2, and March 30, 2011 via a third-party online collection site.

Source: “Physician Compensation Report 2011,” Medscape

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.